-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MdljJQFp8cTIB5R7YVthwwZw2vPCsUBWyY9Bp7r2Ad9ZUz9r+jkxyaNxqzzYQigc
 8GM2szQiopUBW45wtN5v1A==

<SEC-DOCUMENT>0001193125-10-118949.txt : 20100513
<SEC-HEADER>0001193125-10-118949.hdr.sgml : 20100513
<ACCEPTANCE-DATETIME>20100513160621
ACCESSION NUMBER:		0001193125-10-118949
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100513
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100513
DATE AS OF CHANGE:		20100513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD RESEARCH CORP
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21898
		FILM NUMBER:		10828574

	BUSINESS ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101
		BUSINESS PHONE:		626-304-3400

	MAIL ADDRESS:	
		STREET 1:		201 SOUTH LAKE AVENUE
		STREET 2:		SUITE 703
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K </B>
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): May&nbsp;13, 2010 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Arrowhead Research Corporation </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21898</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>46-0408024</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>201 South Lake Avenue, Suite 703, Pasadena, CA 91101 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (626)&nbsp;304-3400 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4 (c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations and Financial Condition. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;13, 2010, Arrowhead Research Corporation announced and commented on its financial results for the quarter ended March&nbsp;31,
2010. A copy of the press release is attached hereto as Exhibit&nbsp;99.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In accordance with General Instruction B.2 of
Form 8-K, the information in this Current Report on Form 8-K, including Exhibit&nbsp;99.1, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange
Act</U>&#148;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof,
except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. </I></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated May 13, 2010.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;13, 2010 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARROWHEAD RESEARCH CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;K<SMALL>ENNETH</SMALL> A.
M<SMALL>YSZKOWSKI&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Kenneth A. Myszkowski</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Chief Financial Officer</B></FONT></TD></TR></TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g14775g83b95.jpg" ALT="LOGO"> </P>
 <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;13, 2010</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact:</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brandi Floberg</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Piacente Group, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">212-481-2050</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ir@arrowres.com</FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARROWHEAD REPORTS FISCAL 2010 SECOND QUARTER FINANCIAL RESULTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PASADENA, Calif. &#150; Arrowhead Research Corporation (NASDAQ: ARWR)</B> today announced financial results for its fiscal 2010 second quarter ended
March&nbsp;31, 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;During the fiscal 2010 second quarter, Arrowhead took a remarkable step forward,&#148; said Christopher Anzalone,
Arrowhead&#146;s Chief Executive Officer. &#147;In March, our majority-owned subsidiary, Calando Pharmaceuticals, announced data that demonstrated first proof of systemic delivery of siRNA and gene silencing via RNAi in humans. This is an exciting
milestone both for our Company and the broader industry. It had long been our goal to be the first company to demonstrate systemic delivery, and we have now achieved that goal. Positive industry and market reception has been encouraging and provides
further validation and recognition of the potential value of this remarkable achievement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We also continue to make progress with
Unidym, following the prior achievement of our goal of initial market entry in calendar 2009 with our first sale in December of our transparent conductive film product in the touch panel market. Since then, we have continued to work with
manufacturers to integrate our product into their devices and make connections in key Asian geographies as well as with potential U.S. partners to increase our market traction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;As we look to add to our portfolio of nanomedicine subsidiaries, we also welcomed two new members to our Scientific Advisory Board: Nobel laureate
Dr.&nbsp;Leland Hartwell and former commissioner of the FDA, Dr.&nbsp;Andrew von Eschenbach,&#148; continued Dr.&nbsp;Anzalone. &#147;These esteemed gentlemen, along with the preeminent leaders in nanotechnology already on the Board, are expected to
play a key role in refining Arrowhead&#146;s strategy as we increase our focus on the opportunities to develop medical applications based on the advances in materials engineering at the nanoscale.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECOND QUARTER FISCAL 2010 AND RECENT COMPANY HIGHLIGHTS: </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Business highlights:</B> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Calando announced what it believes to be: (1)&nbsp;the first proof of gene silencing via RNA interference in humans; (2)&nbsp;the first proof of
systemic delivery of siRNA in humans; and (3)&nbsp;the first dose-dependent accumulation of systemically administered nanoparticles in target tissue with results published in the premier science journal <I>Nature.</I> </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead added two members to its Scientific Advisory Board, Nobel Laureate Dr.&nbsp;Leland Hartwell and former U.S. Food and Drug Administration
Commissioner and National Cancer Institute Director, Dr.&nbsp;Andrew von Eschenbach. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead appointed Kenneth Myszkowski, MBA, CPA, as its Chief Financial Officer. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unidym&#146;s transparent conductive film-enabled touch sensitive MP4 players displayed at the
75</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> China Electronics Fair. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unidym entered into a joint venture with Wise Power (KOSDAQ: 040670) to market and co-develop Unidym&#146;s proprietary film and electronic ink
products in the Korean touch panel and display industries. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unidym added Dr.&nbsp;Malcolm Gillis, former president of Rice University, to its Board of Directors. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial highlights:</B> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decreased consolidated quarterly operating expenses by 58% versus the prior year&#146;s quarter from $5.4 million to $2.3&nbsp;million.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decreased, on a consolidated basis, cash used in operating activities from $11.3 million in the prior year first half to $3.4&nbsp;million in the
current year first half. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SELECTED FISCAL 2010 SECOND QUARTER FINANCIAL RESULTS </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the quarter ended March&nbsp;31, 2010, Arrowhead reported revenue of $157,000, compared with $236,000 in the quarter ended March&nbsp;31, 2009. The
prior period revenue included $118,000 in revenue from grants, which were not repeated in the current period. The sale of carbon nanotubes by Unidym comprised comparable revenue in both periods. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses for the quarter ended March&nbsp;31, 2010 were $2.3 million, a decrease of $3.1
million from $5.4 million during the quarter ended March&nbsp;31, 2009. The significant reduction in operating expenses was a result of measures undertaken by management during 2009 to streamline its businesses and better align its cost structure
with its capital resources. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss for the quarter ended March&nbsp;31, 2010 was $2.1 million, or $0.03 per share based on
62.9&nbsp;million weighted average shares outstanding. This compares with a net loss of $5.3 million, or $0.12 per share based on 42.9&nbsp;million weighted average shares outstanding, for the quarter ended March&nbsp;31, 2009. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONFERENCE CALL </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company will
conduct a financial announcement conference call on Thursday, May&nbsp;13, 2010, at 4:30 p.m. Eastern time/1:30 p.m. Pacific time to discuss the Company&#146;s results for the second fiscal quarter. To participate in the conference call, please dial
877-407-4134 toll free from the US or Canada, or 201-689-8430 from outside the US. Investors may also access a live audio webcast of this conference call on the Company&#146;s website at www.arrowheadresearch.com. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A replay of the webcast will be available approximately two hours after the conclusion of the call. The webcast replay will remain available for 90 days.
An audio replay will also be available approximately two hours after the conclusion of the call and will be made available until May&nbsp;16, 2010. The audio replay can be accessed by dialing 877-660-6853 toll free from the US or Canada, or
201-612-7415 internationally, and entering account number 356 followed by access ID number 350589. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>About Arrowhead
Research Corporation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company
commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two
majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held
nanobiotech companies. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This news release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as
a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative,
regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Arrowhead or its subsidiaries will be able to sustain operations for expected periods,
that we will be able to achieve or sustain targeted levels of expense reductions or that any of these entities will be successful in obtaining additional funding needed to sustain operations. Arrowhead Research Corporation&#146;s most recent Annual
Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any
forward-looking statements for any reason. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>#&nbsp;#&nbsp;# </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g14775g83b95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g14775g83b95.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.P!V`P$1``(1`0,1`?_$`+<``0`!!`,!`0``````
M```````(!`8)"@$%!P,"`0$``04!`0``````````````!0$#!`8'`@@0```&
M`0,"`@8&!0T!``````$"`P0%!@<`$0@2"1,4(3$5-18W-&4V5A<X02(C9@I1
ML>$R0F(S0U1D585&&!$``@$#`@,$!P,("`<``````0(#`!$$$@4A,09!43(3
M87$B,Q0T!T(5-H%28D-C5#46D;'!PM(C4W/PT>&"HL-$_]H`#`,!``(1`Q$`
M/P#?XTI32E-*4TI32E-*5P([!O\`T?SZ4J+2?,;!:N00Q^2VL15%]['+8?--
M?A\\WYH6?LXKP%1W(*X=(.MO*B;T`I^G6(,V`S>2";WM>W"_=>M('U"Z9.[_
M`'0)QJU:/,_5Z[VTZN5K\-?AOPO4I0'<1#^3676[USI2FE*:4II2FE*:4II2
MFE*:4II2FE*:4J$?.+/DMAW&Z<#48F^2-XR"1]%1+^DXTN.1PK46@5(LU,2:
M--GJK)P[A1HY%&/73D4%B.C@H0#`D;:.W',.-%9`YE;@-*EK>FP(]5[UHO7^
M\9FV;*V-MJY)W#)#(KPX\D_EBWM.PBDB93IN$82*0Y!%[5A&&%RB2C)9)&OY
MB"`4MJE0(8N"N1(V()I"-),"\&#+R0]N)Q?AFZ"R`I@B9T44P/UAK7+S"(3A
M9-&JWNGO?G>WF?\`2OF7^3-Y&!]Y&3<?*\WR[#%S_,U!0U]/WGK"\?'^=<<Z
MSC\)<]2>9\8^S;7$WF-O-!!E"3[NZXWMV.!L3-1-7V+.1;2X3=FDI05&3<$7
MJYY!PL9ZF<ZG2"A-]DV[+.5#[0<2)P.I2M^X@&_9SX\[U].]!;SE;ILB0;BN
M0-RQ@$=Y8)(/,MX759))6-U`#,9&)<$FUQ4SM2%;O32E-*4TI32E-*4TI32E
M-*4TI32E=!:K''U"MSMIE2NU(ZOQ+^7>(Q[55](.$6#=1P9K',4`%=](NA("
M:"!`$ZRQBD*&Y@TXVX<Z\2.(T+MX0+UK`3J&5^<')UD\M/%GD#575^FF$,,_
M(96N=1J5"HT4!B@^<L4<?#&QJ49$E4<*(E6.+J16$A3&.J76N3X4V9D>9+'(
M`QMX[`#U6KF.7M:=0[KYN5CY(=R!J\QE5%'*PT6%N?/Q&]ZV*%^.6+E\`FXV
M&C9,F,OA`M/*DG+O"V!-L398DV2?ZA>!92RA?/><])A>?M!*(?JZFOA(?AOA
M1?RM-N?'UW[^V];^=IPCM?W.5/P/EZ+7-[=]^=[\;]_&M=BG*97X0\FI![7>
M*G(*QN:/,R5:>S+/*-SN=3O%%E%2)J2L?'KT`D?+)2,6"3UJF*R8H/TBD,<I
MDSAJ&@PLC#R/,ACD8#AQ<D$'T5H.%MR=/[J9L;'R25NI/F.ZLI]!3C?@1QX$
M5M"5V=C[1`0UCBA7&-G(QE*L@=-U6;LC=\W3<)HO&2Y2.&3U$%.A9%0I5$5"
MF(8`,40UL7'MX&NG(ZN@=?"17<Z5ZII2FE*:4II2FE*:4II2FE*:4K4][Z?<
M*PC8[B/"1'D)8<9AC>8B[!FI"MXDF;\C/V5>+9S%3J:LY&W.LI(M*XUD"OGK
M7PU0.]4;@8P&;F*'1NENC=SSL4;J<=9()`=&IPO`$@M:QYD</^1KA/U*Z_V3
M'S/Y<;,>"6%@TNF%I+D@%5N'3PWN>?&PY@U%OM?]S#ML\&&UR=VVZ9UR[F+)
M<M&P1+C&X32A8>OTQ)9N6-K$2TE\AOWZ1W\RJ9W(KB;9<Q$"`79`!-(;MT!U
M#DD/!#!%CHI-C)<D\R2=/]`J"Z1^IO1.QAUR)\O(SY6`U"'2JKV*`9">?%CV
M\.'"MUM5XDBQ4D#@?P$FAWA@`H"IX1$17,`%WV$_0'JW]>N56).D>*OI$N`G
MF'PVO_;6DKW.^Y7VV.=84>=I5WSKB#+^/WCZ`>6V4PF2:AK-2%E'"J]=EF4/
MD5B\.[B9H`<QSC<02!9P0Q1!4!)U?:OI]U%B$OD0PRP,MP/,L;]]RO`5\V=6
M_4WHG??+.-D9>/FQ$C48;JRF_`@2`W!XJ;\.-Q4R.Q3W"L*1ME#@\KR"L.4'
M-TD9JS8/1L>)9B@IP4FTC'T]=*:E-R5QLR;EO+MV:DDP;="0$<$=@!A%4A-1
M?571VY8&+]Z_#B.!.#V?7S-@UK"W$V)K8OIIU]LV7E?RVN8\\\I+0ZH3'8@%
MG6Y=KW`U*+"W$=HK:MUSL&]=SII2FE*:4II2FG*E-*4TI32E-4/*E8+N9G\/
M[PSYHYYM?(FTVW->-KU?"QR]V:8ULE7;5RP3$9&M(=&PGC+-3[&JPEG4;'HI
MN1;K)HKF3!04P4,<Y]\V+ZB[YLFWIML"P2X\=]/F*Q8`F]KAEX7/"_\`57-.
MHOI5TOU+N3[KF"9,R2VHHR@$@6O9E;C8<;<+\;7)-1@8_P`+!P@8/F+]+.?*
M@ZL>^9OD2GLN,A3,JR<I.4RJ`&,0$4S'2`#;"`[>H0U+M]6NH&4CR,3B"."O
MVC_<J&C^B'2$4@D1\H.IN/:3_!6S&JR35CE(XQU`249'9&4`0\4$SH"@)P';
MI\0"COZMM]<MUV.KMO?_`(%=B*`IH^S:U:S"_P#"N<'W+ARY4SKRH!1TY7='
M*2R8R*4IW"IUCE(`XP$P%*938-Q$=M=27ZM;^HL(,/\`*K_XZXZ_T0Z0D8N[
MY18DGQ)V_P#94K^%'8)X:\(\[5[D34+3FC).0:8VE24HF3+)674!69":C'D*
M^G6T56*E6Q?2Y8F0700.Y5520!8QRI^)T')#[Y]0][W[`;;9U@CQG(U>6I!8
M`@@$ECPN`>`!/;PJ<Z<^EG3'3.Y)NV$)7S(P=)<J0I(*D@!1QL2.)MV\[5G%
MUHH%N`KI%-*4TI32E-4N.=*C)S'Y*5_B-QMRGGJ=:&F'5-@/!IM3;@922OF2
M;"Z;UW&]`AVR1@<NY2Y7648L$R)`90`7$^VQ!VD]HVR3>-RBV^,V#M[3=B(`
M2[GN"J">/=4;N^XQ[5MTN<XN47V5[6<\$4#M+,0.'KK7OQ#W.^7_`!7Q/GW'
M')EM=;9R-0C\#9EP%(<I\92F)"W"'RYD?%^).05&BX*ON6#R:J7'[(UT46A5
M6Z@.GL*Z1%82^$8`Z#F=+[-NF9CY&ULB;;>6.7R7\S28T>2)R6`LTJ+9NQ6'
M#G6@8_5&\;5B9$6YH[;@!%)%YRF/4'9$E4`$DB-F)![1W=F1%MR_[BK?DK!\
M:Y+!_&*0N=0PY"9XR_&0%PR`=2SXVDN1EOQ2J_Q)+.]VD58U<;P+:>;Q4PW=
M&&15.P,OMTK!KK;3T[]V-N2SY0A>8Q1DJG!Q"KVD%^(UDH2IY>U;LK8EW;J#
M[P^[G@QC,D0DDTLW%#*R>P3VZ!JLW;PJ(]9[RO*.Z5Z-GZ%BKC5D^Q7;!N;<
M_ML)8_M609++G'&&P%8(1U9L<<FF*_0WC+[;Z:XD&$49-"(Z+8T!J#5VV-XP
MS$O1NUP2&.>;)BC2>.+S'5!'*90;/">U%8`MXO8-[@U#Q]8[G*H:"+&E=H)9
M=",Y>(1$727AP8K<#E[8M8BKTH_>9RGFK)U>QGB["];*PY/9&@G7!V\3(VLC
M+(_%VJ3-_A>1N;KRV1,D:OS&.DL<KNXQ@4R(.DIB.%0!*8XFLS=&8F%C-DY<
MYU8T9^)5=)T3,$,,:G[0?6`QXVTM5^/K#*RYQCXL'#(?_(9@PU1J7$KMSL4T
M7`-KWY<":\"PSW;^7F#N*V/;-F6BTODI+6K@=:.56/+17G]JB<B2*M/S10,5
M22>;&PQSN"69,FF2$I=^_@T6R;=I&+E\(I3`J20SND=GS=VDCPY'Q8USU@=2
M`4&J)I!Y?;]@J`YYD>JH[!ZMW;#VA)\Q$R"V"TZ,+ASID5/\SLY-<E>P'UUZ
MG-]YK+\90L?N4'?'!;)=\L64$(N*/77IJ.^KV/*O1)A8?CA#DP>EP4TE(6L2
M';/9OVD[;J)G;QW2DH<^-'T5B/E2(3D?#1JA)N-5W+`>SY6HBR\PMK\"U7SU
MKF?#1NJX_P`1([`"QTV55-]7FVO<\B;VL;5'[D/WJN0&4.*%PG\;J88XDV1[
MPOQ3GZ)L%YO$PODW(]MR1/V*&G*]Q28.8^-KUG5H+NIG1=KO?:"Y%7R:9V@`
M`J#F;?T5MV/N:KD^?EQC-EBLJC0BQ@6,YYKKU<+:>1XUB;CUGN$^W/\`#F#$
MF^#24%F.MV?F(!:S:;6-[FYY5D+[E>1>2R69>W'B/`EMS(T<9P+R+<WNI83R
M+C+$]TOQ,?8DJENAP3OF5JG;JG$$@GRSAV=-1J4SI,QT2&*<Y#%@.E\;;?@-
MRS<](2(/)TM*CR*NN0J?8C96)(`%P>'.M@ZBR-R^,V_%P7F!F68LL;HC-I12
M/:D!46N38CCQJ`>,>[1RDPK@C#S"V^SLAV?+F>.6]?2MW(.2@G=OXZ53!,E7
MHV$X_9]<5U7`E4L'(51\_=.E5?.1:)HCP54"/@-N6?GZ0VO/W&8Q'RHXL;';
M3$#IF:6]Y8M1E98>0Y'VN=J@(>K-RV_`@$@,LDL\ZWE(+1+%:T<EO+!D/._`
M:>0-2P-W<LS07)6HXKOE7P;#4.T77$%-K?P3((9;R7D-7(U#KMB\TPK=$S0_
MG<;OIBQRJ[%HVD8*5;1:!4G+MZJW/XVHD=(X<NU29L#S&=$D9@P\M$T.5L2T
M=G``!)5AJY*+\*E1U;F)N:8<Z0B!V0#2=;-J0-P"O=23<`%2!VFO(\?=\;*E
MOP[?<O6ZLX:Q2HU+3VM1H$E!3EUL=4LEQRU'X_CZME`\3F:!EHUPDT743=R$
MG$52,CWXE%PL5,"D6S<KH7&@S8L.%Y90VK4X(4%5CUEDNC`]X`9R1R':,'&Z
MZR9L67)GCBB*VTJ0206?2`]G%N':0@!YGONC&_=VY=9P3H>.\2XFXWNLVVOD
M_GKCTV>6*QV=;&%D#%/&F.Y$5B2C'5-MEH-7WEI%][&=&]K331DH`.`.<`.B
M6SF=(;3MQ?(S)LGX%<:*7V0NL>9,8F!#!;A;:AP4GEZ:OX?5^[;@4Q\6"#XQ
MLF2.[,=!"1>:#[):Q/A/%@.?HJ\;_P!R?D';X?G%4%K)Q@XRVOCQ2\\TYMBJ
MPWJ??<N++<*!QWD+VCE7$,1(&@ZM)4IU;%A<0+D(Z53=1<:JNJ8IAZ"V(.FM
MOB.#-IRLF+(>)O,5`,=5>4)HD878,%\8N+,;>FK\_4F=*,S'+8N--`DBZ"Y,
MY98BVN,&RE;^$\;@$FNRQWS4YJV/!')+$UC<8/;YVQ=V\\&\K,>YG@S7LT9)
MPN4*I<#SIKK7WY_.(9+BF5">O6;QBM[*4DW*)E&X(D43-XR-EV./<<;(B\\X
M$NXRP/&=%P49;:6!\!U@&_&P/&]JN8^[[W)@Y.+(8!G18$<R2`M8AU:Y8'[8
M"D@CV=5N%JSWO8Z/DDTDI%BS?I(.4'B*3ULBZ31=M5`5:NDB+D4*FY;*@!DS
M@`&(;T@(#K1%9E-U)!M;A6]%5;@P!%4LC`04PJ@M+0L3*+-0,5JK(QS-ZJV*
M<Z2IP04<HJF1`ZB!##TB&YB%'U@&@=E\)(JC(C^,`^L7JL!BR!Z:2!FU"0.V
M*S,_!ND#TS,BIEB-#.NCQQ;%6,)P3$W2!A$=M]4U'3IN=-[V[+U6POJL-5=>
MSKM>C7DI(Q\%#,)"<4!6:?,HQBU>3*H`8I5)1R@@FM(*`!Q`!6,<0`1U5I)&
M4*S,57D+\O5W5Y$<:DE5`+<[`<?7WU$.;Y08]J"US7'%CPL+BI>]UMA,,7V-
M&SA>1J$C"0\_#P4`M9&MAB8]\^F4BE7.W1:BF05%A3()!-&R;J%,@8.54D'B
M/:86X6+7/$CB1;TUS?,^HNVX#9KOA3'%P7FC+A\8:GA:-'58S,)5!:06=D"`
M79RH*DV?=.:N,,7M##9,42<7*0DE:*8ZBXYS09%&/;0]:I-O<,8^8AIAW$N&
MT\UO,<BW:)J$\1\(HJ@0P$$UF;>XX%+2K('UD$74\556YAK<G`'&]S:HK=OJ
MYLNQ1,=QPLA)XYI860-`X!BA@F.ETE*-YBY,2(H-S*2A"FUZ.6Y6X5C'UYJB
MF`IYU#4*;E&<BX3IM32K7Q4R>52"!%XL]6;0\([DWUK;-DG#I4AA\)0#]($#
M>XV_%7>XGU(2I-^X@6N2+"["U[#G5^?ZH;-CS9D#;=F&'"=D9_+C">8K0IH)
M9PJ%FF507(%U>]M-?'(',?#5+C6C&YX8<G<P%BN%6+7R(X]G6L._J\)CV?7;
MP3QA)OX=RO/-\DQ:#)!N<AUGIC('Z#@7J\2;\N/<L)1)J8$`B]U"GL;C?6+<
M>?#G6-O/U<V/98PNY8,XR%EGC9`T#V:!,5R%=9"CM)\7"L2J;M(2A`8"]]SG
M-#$A)G*["#K<A<K/@"+/.3+-HO46DB>#20%G>'U67EIAN85*7)`G&RJ`BW5%
MPH0J8*I_K:]/O$"^<B:F:(78`@7`\1%R+Z3P-^1/Y:S\SZK].PS;KCXD<N3F
M;/%YDJ(T(9D7A.T1>103CO:.56TD.0%#`WJNL>?Z4WG!QW)875DKC,V5HWE:
MK(.L:H1IYY7'1,BN7\G.S$VA7WCEE7C)I>-XBBBBP])!$A1-J]]ZF.;R5649
M`LMK@6NNJURP'+N//^FL[,Z[Q<;-7:),"9MV:94,1?&4!SC')),CRK&=,8M<
M$W8V6X!-6S5N67'F1M%';M<>/:[9KTKB1I2Y9W4(!HE+/,J1,>Y90T99V*J[
M0TY4H5^DK(,07*OY`!5:E<(D4$EI=]B?3"QE`?1IOX6,EB`#>UP&!8<[<1>H
M_#^JW2N3FXV$T.1#E938:PEXU"2/F(KK''(&*&2%'#2QW#!+O&)%#$324I]1
M56DW*M6KBCB;3%*974A(PZTND94BYDI-4S43OTS+I%.)51.`G*`^L`U+>;+8
M#4UEY<3P]7=74O*BN3I6YY\!Q]=?2/JE6B`;A%5J`C`:.%7;0(^'CF0-72Z'
ME5W+<&S9+P'"S7]F<Y=C&3_5$=O1JC2.W%F))[S18XU\*@>H"OV^K%:DWQ).
M2KT'(22;=1HG(/HE@[?$:K)JHJMB.UVZBY6ZJ*YR&(!NDQ3F`0V$=!)(%TJQ
M"WO:YM?OH8XV.IE!;OL*JBPT.05C$BHTAG#!**7,5BU**\6W*H5"-6$$@%1@
MB58X$1-NF4#"``&XZIJ;O/._/M[_`%U70G<.5N79W>JNRUYKU32E-*4TI4%I
MSYD9E_(M]E;+[]^9'^#$_.7]UO\`D_[G@:B9?F'^4\+<_'R'B]'YWHM7&L[\
M0[S^#/E)?>?-^&/^(_L/]7]'RZKL??+63_)+[MR5\OM_PU]V5GWI]6_>7_;>
M2U6#W)^4^UX/#R7G_>]&FL[IW\-2?A/P9GR?R?AB\?Z/[Y^CY=>M3>WX1Y#^
M0/TF7V]N=7X2?UF7S&W]/FMOIF_]KPM9,WRTGN?M>+P<_M_WJV7</PSG_P`&
M_6>]^2[/FO\`V?DKRFA[?ANY_)5[HR1]A-_PV_\`(_2OJG[R?]?K'Q_<-\KR
M?P>'F.?H_/\`3:M:Z?\`PXWX3]UE_*?)\X.?Z'[WZ?(J^3;?#<!^6/[)Y+VW
MZOASZ:R]Q_I^$OO-O_G^'J^W@_4^!N?+L_\`'\[TVJ=;Y2+^!?+9?^WS7P?L
M?WO]+35L9ZV\K*[?_'GVJ@_GYU>7^QX^]>KT_%7^@^I]6L_P_P#S>+];ZOZ_
M[*B.N?<2?A?YF+^)^'W)\?[;_2_8WJ^(/W15_P`N7O\`Q1[C]S^X&GV7_>#[
MJ?5_AZN1^%?<<TY<N0Y>G\ST6J;Q?E,;^">^Q/![OW2^Y_:?N?[+34C=9U;M
)32E-*4TI7__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
